Skip to main content
OpenTrials
Completed

NCT Number: NCT03669042

Post-market, Prospective Evaluation of PHOTO-oxidized Bovine Pericardium in Vascular Surgery

The objective of this post-market clinical follow-up study is to evaluate the clinical outcomes of patients receiving PhotoFix as a patch within a vascular repair or reconstruction procedure.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Arizona, Tucson, Arizona, United States

Loading trial locations.

About this study

PhotoFix is prepared from bovine pericardium, which is stabilized using a dye-mediated photo-oxidation process and sterilized using aseptic processing techniques. The primary endpoint for patients with carotid artery stenosis (CAS) undergoing carotid endarterectomies (CEA) will be rate of ipsilateral central neurologic events; the primary endpoint for all other vascular procedures will be primary patency. The secondary endpoints include all-cause reoperation rate, device-related reoperation rate, explant rate, restenosis rate, secondary patency (hemodialysis access repair (HAR) only) and survival. A goal of 100 patients will be enrolled at approximately 10 sites. The enrollment period will span a minimum of 8 months from Institutional Review Board (IRB) approval and site activation. Candidates for this study are adults who require vascular repair or reconstruction surgery that necessitates the use of a patch. Patients will be consented pre-operatively and enrolled patients will be followed for approximately 6 months after PhotoFix surgery. Data will be collected at 5 time points: baseline (pre-operatively), intra-operatively, 1 month post-operatively, 3 months post-operatively, and 6 months post-operatively.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient is undergoing a vascular procedure which falls within the indications for use and requires the use of PhotoFix Decellularized Bovine Pericardium
  • Patient's surgery is anticipated to occur within 60 days of consent
  • Patient is ≥18 years old
  • Patient is willing and able to comply with the protocol and follow up period
  • Patient is willing and able to give written informed consent

Exclusion criteria

  • Patient's procedure is a revision of a prior arteriotomy or venotomy
  • Patient's procedure requires multiple vascular patches in anatomically distinct regions or other prosthetics (e.g. stents)
  • Patient has a medical history of abnormal coagulopathy, bleeding, or thromboembolic disease
  • Patient has a medical history of severe immunodeficiency disease
  • Patient has a medical history of cancer
  • Patient has severe visceral disease in heart or active liver disease or icterus
  • Patient has a history of cerebrovascular accident (completed stroke) within 3 months of planned surgery
  • Patient has a history of atrial fibrillation and requires a patch for carotid endarterectomy repair
  • Patient has an active or potential infection at the surgical site
  • Patient has used or plans to use immunomodulatory drugs for ≥ 6 months
  • Patient has a sensitivity to products of bovine origin
  • Patient is currently enrolled in another study
  • Patient has a life expectancy of less than 12 months
  • Patient is pregnant or breastfeeding or planning on becoming pregnant or unwilling to use medically acceptable methods of birth control
  • Patient's procedure is emergent

Treatment and study plan

PhotoFix

Device

PhotoFix Patch Implantation

Primary outcomes

  1. Incidence of Central Neurologic Events

    Time frame: Up to 6 months, post-op

    For cases of carotid endarterectomy (CEA) only: Percent of patients who experienced at least one of the central neurologic events of interest (transient ischemic attack, amaurosis fugax, stroke, carotid occlusion).

  2. Primary Patency

    Time frame: Up to 6 months, post-op

    For all other procedures (non-CEAs): Loss of patency includes loss of previously palpable pulses, presentation of recurrent symptoms, a drop in ABI>0.15 in the case of lower limb artery repair, Doppler ultrasound findings of occlusion, angiography of the affected vessel or a combination of these. Loss of patency will also be considered if an intervention to restore or maintain patency is documented.

Secondary outcomes

  1. Overall Survival

    Time frame: Up to 6 months, post-op

    Percent of patients surviving

  2. All-Cause Re-operation Rate

    Time frame: Up to 6 months, post-op

    Percent of patients requiring re-operations

  3. Device-Related Re-operation Rate

    Time frame: Up to 6 months, post-op

    Percent of patients requiring unplanned re-operations that are documented as possibly, probably or definitely, device-related.

  4. Explant Rate

    Time frame: Up to 6 months, post-op

    Percent of patients requiring device explants. Explants will include the removal of PhotoFix for any reason after implantation.

  5. Adverse Event Rate

    Time frame: Up to 6 months, post-op

    Percent of patients who experienced at least one adverse event.

  6. Restenosis Rate

    Time frame: Up to 6 months, post-op

    Percent of patients who develop stenosis. Stenosis is considered as the recurrence of abnormal narrowing of an artery or vein after corrective surgery. Categorization of stenosis ≥ 50% will occur if data is available.

  7. Secondary Patency

    Time frame: Up to 6 months, post-op

    For all hemodialysis access repairs only: Time from implantation to the point where the access is abandoned.

Sponsors and collaborators

Lead sponsor

Artivion Inc.

Industry

Registry information

Official study title

Post-market, Prospective Evaluation of PHOTO-oxidized Decellularized Bovine Pericardium Used as a Patch in Vascular Repair and Reconstruction Surgery

Acronym: PHOTO-V

Important dates

Study start
2018
Primary completion
2020
Study completion
2020
First posted
Sep 13, 2018
Registry last updated
Oct 8, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.